LEADER 02194nam  22005534a 450 
001 9910780632703321
005 20230721024016.0
010   $a0-19-770561-8
010   $a1-282-54350-4
010   $a9786612543500
010   $a0-19-970975-0
035   $a(CKB)2430000000023009
035   $a(SSID)ssj0000352643
035   $a(PQKBManifestationID)12125598
035   $a(PQKBTitleCode)TC0000352643
035   $a(PQKBWorkID)10286002
035   $a(PQKB)11241248
035   $a(Au-PeEL)EBL2012712
035   $a(CaPaEBR)ebr10375226
035   $a(CaONFJC)MIL254350
035   $a(OCoLC)923712683
035   $a(MiAaPQ)EBC2012712
035   $a(EXLCZ)992430000000023009
100   $a20080618d2009      uy             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 10$aAnkylosing spondylitis$b[electronic resource] /$fMuhammad Asim Khan
210   $aOxford ;$aNew York $cOxford University Press$dc2009
215   $axii, 147 p. $cill
225 1 $aOxford American rheumatology library
300   $aBibliographic Level Mode of Issuance: Monograph
311   $a0-19-536807-X 
320   $aIncludes bibliographical references and index.
327   $aIntroductory overview on ankylosing spondylitis -- Epidemiology of ankylosing spondylitis and related spondyloarthropathies -- Causes of ankylosing spondylitis -- Disease process -- Clinical features -- Physical findings -- Diagnosis -- Other manifestations and complications -- Descriptions of related diseases : the spondyloarthropathies -- Assessment of disease activity -- Disease management -- New treatment : remarkable efficacy of TNF-a antagonists -- Other aspects of disease management -- Socioeconomic aspects and prognosis -- Brief illustrative case histories.
410  0$aOxford American rheumatology library.
606   $aAnkylosing spondylitis
615  0$aAnkylosing spondylitis.
676   $a616.7/3
700   $aKhan$b Muhammad Asim$01568380
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910780632703321
996   $aAnkylosing spondylitis$93840508
997   $aUNINA